经导管二尖瓣置换术在瓣环钙化、瓣环成形环及生物瓣中的2年结局
MITRAL试验是首个评估球囊扩张式主动脉经导管心脏瓣膜用于二尖瓣环钙化(ViMAC)、二尖瓣环成形环(MViR)及二尖瓣生物瓣(MViV)的前瞻性研究,纳入91例高危患者。2年随访显示三组全因死亡率分别为39.3%、50%和6.7%,症状与生活质量持续改善,瓣膜功能稳定。
要点
- ViMAC、MViR、MViV三组2年全因死亡率分别为39.3%、50%、6.7%。
- 三组2年时NYHA I-II级比例分别为66.7%、65%、85%。
- 所有患者2年时二尖瓣反流≤轻度,瓣膜功能稳定。
核心结论
- 在严重MAC、瓣环成形环失败及生物瓣功能障碍的选定患者中,使用球囊扩张式主动脉经导管心脏瓣膜与症状、生活质量改善及2年瓣膜功能稳定相关。
- MViR组在1至2年间的死亡率高于MViV和ViMAC组。
研究设计与样本
- 多中心前瞻性研究,纳入13个美国中心的高手术风险患者,共91例(ViMAC 31例、MViR 30例、MViV 30例),评估2年结局。
主要发现
- ViMAC组2年全因死亡率为39.3%,66.7%为NYHA I-II级,平均二尖瓣跨瓣压差为5.6±2.0 mmHg。
- MViR组2年全因死亡率为50%,65%为NYHA I-II级,平均二尖瓣跨瓣压差为6.5±2.7 mmHg。
- MViV组2年全因死亡率为6.7%,85%为NYHA I-II级,平均二尖瓣跨瓣压差为6.9±2.4 mmHg。
- 2年时所有患者二尖瓣反流≤轻度,三组存活者堪萨斯城心肌病问卷评分较基线持续改善。
临床怎么用
- 对于高手术风险的严重MAC、瓣环成形环失败或生物瓣功能障碍患者,可考虑使用球囊扩张式主动脉经导管心脏瓣膜行经导管二尖瓣置换术。
- MViR患者术后1至2年死亡率较高,需加强随访和风险管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The MITRAL (Mitral Implantation of Transcatheter Valves) trial is the first prospective study for valve-in-mitral annular calcification (ViMAC), mitral valve-in-ring (MViR), and mitral valve-in-valve (MViV) using balloon-expandable aortic transcatheter heart valves. Procedural outcomes beyond 1 year are not well described. OBJECTIVES: This study evaluated 2-year outcomes in ViMAC, MViR, and MViV in the MITRAL trial. METHODS: This multicenter prospective study enrolled patients with severe MAC, prior failed mitral annuloplasty ring repair, or prior failed bioprosthetic MV replacement who were at high surgical risk at 13 U.S. sites. RESULTS: Between February 1, 2015, and December 31, 2017, 91 patients were enrolled (31 with ViMAC, 30 with MViR, and 30 with MViV). In the ViMAC group, 2-year all-cause mortality was 39.3%, 66.7% were New York Heart Association (NYHA) functional class I-II, and mean MV gradient was 5.6 ± 2.0 mm Hg. In the MViR group, 2-year all-cause mortality was 50%, 65% were NYHA functional class I-II, and mean MV gradient was 6.5 ± 2.7 mm Hg. In the MViV group, 2-year all-cause mortality was 6.7%, 85% were NYHA functional class I-II, and mean MV gradient was 6.9 ± 2.4 mm Hg. At 2 years, all patients had ≤mild mitral regurgitation and survivors in all 3 arms showed sustained improvement in Kansas City Cardiomyopathy Questionnaire scores compared to baseline. CONCLUSIONS: Use of balloon-expandable aortic transcatheter heart valves in selected patients with severe MAC, failed annuloplasty ring, and bioprosthetic MV dysfunction is associated with improvements in symptoms, quality of life, and stable prosthesis function at 2-year follow-up. Between 1 and 2 years, the MViR group experienced higher mortality rates than the MViV and ViMAC groups.
引用
- Eleid MF, Wang DD, Pursnani A, et al. 2-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Annular Calcification, Rings, and Bioprostheses. J Am Coll Cardiol. 2022. PMID: 36456047. doi:10.1016/j.jacc.2022.09.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。